All Articles
The Geron REACH4RYTELO Patient Support Program can help your eligible patients who have
been prescribed Rytelo navigate access and affordability. Read More ›
SpringWorks CareConnections provides personalized support services and resources to help
patients start and stay on track with their SpringWorks medications. Read More ›
The fight for dominance over healthcare delivery, resources, and decision-making
intensifies as private equity, AI, and corporate consolidation reshape the
landscape. Read More ›
By Denise Danos, PhD; Eileen Mederos, RN; Dina Brackman, RN; Jennifer Gex, RN; Pamela Tuli, MD; Jennifer Manning, DNS, ACNS-BC, CNE; Alison Davis, PhD, RN, CNE, CHSE; Augusto Ochoa, MD
Discover how virtual research nurses are transforming clinical trials in community
oncology, making research more accessible and efficient. Read More ›
Hazardous drug exposure remains a critical challenge, requiring rigorous safety
protocols and a culture of vigilance in healthcare settings. Read More ›
On November 6, 2025, the FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for adults with high-risk smoldering multiple myeloma (SMM). Darzalex Faspro is only indicated for patients with high-risk SMM. It is not indicated for other risk categories. Read More ›
On October 23, 2025, the FDA approved belantamab mafodotin-blmf (Blenrep) in combination with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma. This approval applies to patients who have received at least 2 prior therapies, including a proteasome inhibitor and an intermodulary agent. Read More ›
On October 24, 2025, the FDA approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 years and older with relapsed or refractory acute myeloid leukemia (AML) characterized by a susceptible nucleophosmin 1 (NPM1) mutation with no satisfactory alternative treatment options. Read More ›
Learn how revamped oncology navigation programs improve patient outcomes and
streamline care delivery in cancer treatment. Read More ›
Advances in precision medicine and biomarker testing are transforming lung cancer
treatment, offering hope through targeted therapies and innovative approaches. Read More ›